Studies conducted using a 786-O cell line characterized by a high level of c-Met showed that the combination of anti-angiogenic agent axitinib (which targets all VEGFRs) with crizotinib inhibits tumor growth and reduces vascularization compared to individual therapy with these drugs. This evidence concerns the gene MET and neoplasm.